Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
M&A / Property Routine +

Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec

Cannabix Technologies Inc.

By The Northwire Desk — AI Analysis Jun 15, 2026 · 08:45 BLO · 0.6 Cannabix Technologies Inc.
Executive Summary
  • Cannabix Technologies announced the deployment of its Marijuana Breath Test (MBT) system with a major heavy materials industrial operator in Quebec.
  • The deployment was facilitated through partner Alco Prevention Canada and targets post-incident and reasonable-cause workplace safety protocols.
  • The release emphasizes the industry shift toward breath-based THC detection as a non-invasive, recent-use assessment tool that avoids the legal and operational ambiguities of traditional urine or oral fluid testing.
  • No specific contract value, unit volume, or revenue contribution was disclosed.
Material Impact
  • The announcement represents incremental commercial progress within the company's phased rollout strategy, consistent with prior deployments in Virginia (April), construction (March), and clinical settings (May).
  • Given the company's current revenue scale ($123k CAD over six months) and the undisclosed nature of the contract, the immediate financial impact is negligible.
  • The news does not introduce new regulatory approvals, financing, or strategic partnerships that would alter the capital or commercialization trajectory.
  • Market reaction is likely to be muted, as the stock has already consolidated around $0.60–$0.70 following the March commercial launch spike.
BLO · Price
Company Overview
  • Cannabix Technologies develops breath-based detection technologies for workplace safety and public health.
  • Core products include the Marijuana Breath Test (MBT) for recent THC detection and BreathLogix for unmanned alcohol screening.
  • Target markets are safety-sensitive industries: construction, manufacturing, mining, maritime, transportation, and aviation.
  • Revenue model combines hardware sales (Breath Collection Units) with recurring revenue from disposable breath cartridges.
  • Strategic partnership with Omega Laboratories provides forensic lab analysis and validation support.
Read the original news release →

More from Cannabix Technologies Inc.

Jun 29, 2026 · 08:45

Cannabix scales its breath-based THC and alcohol screening hardware into global mining and industrial sectors, but revenue remains negligible against operating burn.

Production / Operations May 29, 2026 · 08:45

Cannabix Expands Australian Footprint as MBT Certification Progresses Amidst Volatility

Production / Operations May 13, 2026 · 08:45

Cannabix Secures UL/CSA Certs, Clears Path for Gov Tenders Amidst Steady Commercial Rollout

Regulatory May 04, 2026 · 08:45

Cannabix Executes Commercial Rollout Amidst Dilution Concerns

Production / Operations Apr 20, 2026 · 08:45

Cannabix Breath Test Gains Traction in US Manufacturing Sector Following Commercial Launch

M&A / Property Apr 01, 2026 · 08:45

Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client

Production / Operations